Rheumatology International

, 30:357 | Cite as

Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis

  • Young Ho LeeEmail author
  • Jin-Hyun Woo
  • Seong Jae Choi
  • Jong Dae Ji
  • Gwan Gyu Song
Original Article


The aim of this study was to assess the structural efficacies of daily glucosamine sulfate and chondroitin sulfate in patients with knee osteoarthritis (OA). The authors surveyed randomized controlled studies that examined the effects of long-term daily glucosamine sulfate and chondroitin sulfate on joint space narrowing (JSN) in knee OA patients using the Medline and the Cochrane Controlled Trials Register, and by performing manual searches. Meta-analysis was performed using a fixed effect model because no between-study heterogeneity was evident. Six studies involving 1,502 cases were included in this meta-analysis, which consisted of two studies on glucosamine sulfate and four studies on chondroitin sulfate. Glucosamine sulfate did not show a significant effect versus controls on minimum JSN over the first year of treatment (SMD 0.078, 95% CI −0.116 to −0.273, P = 0.429). However, after 3 years of treatment, glucosamine sulfate revealed a small to moderate protective effect on minimum JSN (SMD 0.432, 95% CI 0.235–0.628, P < 0.001). The same was observed for chondroitin sulfate, which had a small but significant protective effect on minimum JSN after 2 years (SMD 0.261, 95% CI 0.131–0.392, P < 0.001). This meta-analysis of available data shows that glucosamine and chondroitin sulfate may delay radiological progression of OA of the knee after daily administration for over 2 or 3 years.


Glucosamine Chondroitin Knee Osteoarthritis Structural efficacy 


  1. 1.
    Creamer P, Hochberg MC (1997) Osteoarthritis. Lancet 350:503–508CrossRefPubMedGoogle Scholar
  2. 2.
    Verbruggen G (2006) Chondroprotective drugs in degenerative joint diseases. Rheumatology 45:129–138CrossRefPubMedGoogle Scholar
  3. 3.
    Reginster JY, Bruyere O, Neuprez A (2007) Current role of glucosamine in the treatment of osteoarthritis. Rheumatology 46:731–735CrossRefPubMedGoogle Scholar
  4. 4.
    Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, Herrero-Beaumont G (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 11:290–298CrossRefPubMedGoogle Scholar
  5. 5.
    Hardingham T (1998) Chondroitin sulfate and joint disease. Osteoarthr Cartil 6(Suppl A):3–5CrossRefPubMedGoogle Scholar
  6. 6.
    Bali JP, Cousse H, Neuzil E (2001) Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum 31:58–68CrossRefPubMedGoogle Scholar
  7. 7.
    Vlad SC, LaValley MP, McAlindon TE, Felson DT (2007) Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 56:2267–2277CrossRefPubMedGoogle Scholar
  8. 8.
    Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, Dieppe PA, Juni P (2007) Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 146:580–590PubMedGoogle Scholar
  9. 9.
    Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16:137–162CrossRefPubMedGoogle Scholar
  11. 11.
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC (2002) Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162:2113–2123CrossRefPubMedGoogle Scholar
  12. 12.
    Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251–256CrossRefPubMedGoogle Scholar
  13. 13.
    Kahan A, Reginster JY, Vignon E. STOPP (Study on Osteoarthritis Progression Prevention): a new two-year trial with chondroitin 4&6 sulfate (CS) [abstract]. EULAR 2006 June 23; Amsterdam, The Netherlands: Institut Biochimique SA (IBSA). Available at
  14. 14.
    Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, Uebelhart D (2005) Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 52:779–786CrossRefPubMedGoogle Scholar
  15. 15.
    Uebelhart D, Malaise M, Marcolongo R, de Vathaire F, Piperno M, Mailleux E, Fioravanti A, Matoso L, Vignon E (2004) Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 12:269–276CrossRefPubMedGoogle Scholar
  16. 16.
    Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E (1998) Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartil 6(Suppl A):39–46CrossRefPubMedGoogle Scholar
  17. 17.
    Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315:1533–1537PubMedGoogle Scholar
  18. 18.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMedGoogle Scholar
  19. 19.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  20. 20.
    Corbett J, Gu CC, Rice JP, Reich T, Province MA, Rao DC (2004) Power loss for linkage analysis due to the dichotomization of trichotomous phenotypes. Hum Hered 57:21–27CrossRefPubMedGoogle Scholar
  21. 21.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMedGoogle Scholar
  23. 23.
    Rozendaal RM, Koes BW, van Osch GJ, Uitterlinden EJ, Garling EH, Willemsen SP, Ginai AZ, Verhaar JA, Weinans H, Bierma-Zeinstra SM (2008) Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 148:268–277PubMedGoogle Scholar
  24. 24.
    Conrozier T (1998) Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med 27:1862–1865 (French)PubMedGoogle Scholar
  25. 25.
    Malaise M, Marcolongo R, Ubelhart D, Vignon E (1999) Efficacy and tolerability of 800 mg oral chondroitin 4&6 sulfate in the treatment of knee osteoarthritis: a randomized, double-blind, multicentre study versus placebo. Lit Rheumatol 24:31–42 (German)Google Scholar
  26. 26.
    Ravaud P, Giraudeau B, Auleley GR, Drape JL, Rousselin B, Paolozzi L, Chastang C, Dougados M (1998) Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis 57:624–629CrossRefPubMedGoogle Scholar
  27. 27.
    Towheed TE, Anastassiades T (2007) Glucosamine therapy for osteoarthritis: an update. J Rheumatol 34:1787–1790PubMedGoogle Scholar
  28. 28.
    Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY (2003) Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163:1514–1522CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Young Ho Lee
    • 1
    Email author
  • Jin-Hyun Woo
    • 1
  • Seong Jae Choi
    • 1
  • Jong Dae Ji
    • 1
  • Gwan Gyu Song
    • 1
  1. 1.Division of Rheumatology, Department of Internal MedicineKorea University Anam Hospital, Korea University College of MedicineSeoulKorea

Personalised recommendations